HC Wainwright & Co. Reiterates Buy on ProQR Therapeutics, Maintains $10 Price Target
Benzinga Newsdesk 1 year ago
NewsPrice TargetReiterationAnalyst Ratings
HC Wainwright & Co. analyst Andrew Fein reiterates ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $10 price target.
HC Wainwright & Co. analyst Andrew Fein reiterates ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $10 price target.